Envision Pharma Group appoints Richard Gorman as President, Strategic Consulting

Envision Pharma Group (Envision) has appointed Richard “Rich” Gorman to the role of President, Strategic Consulting and member of the Executive Leadership Team.

Rich is a 30-year veteran of the life sciences industry and a respected leader with a track record of success in pharmaceutical commercialization. He is an experienced head of high-performing teams that build go-to-market strategies to deliver on business development and revenue generation goals.

Rich will be responsible for leading the Strategic Consulting business across Envision’s commercial, medical, and technology sectors. He will lead a team of scientific, medical, and commercial strategists with deep expertise in the life sciences industry while combining its technology and AI platforms to accelerate the business and scientific momentum of clients’ strategies.

Prior to joining Envision, Rich served as Chief Commercial Officer and Global Head of Strategy for Amplity Health. Before that, he held various leadership positions and senior business development roles at Syneos Health. His background includes serving as a CEO for a specialty pharmaceutical company, as well as several positions within the field of contract pharmaceutical development and manufacturing.

Rich shares, “I am delighted to be joining Envision Pharma Group at this pivotal and exciting time. I am honored to have the opportunity to lead this talented team of strategy consultants. Combining their proven capabilities with the Envision technology platform will create a powerful option for manufacturers looking to efficiently bring new science and products to patients.”  

Meg Heim, Chief Executive Officer of Envision Pharma Group states, “We are so excited to have Rich join our team as we continue to accelerate Envision’s business expansion, mission, and commitment to our clients’ needs. Rich’s proven expertise will be critical in partnering with our clients to execute upon their goals, improve performance, and meet their unique business needs with the support of our technology platforms and strategic advisory expertise.”

Close

Envision Pharma Group (Envision) has appointed James “Jim” Streeter to the role of President of Technology, CTO and member of the Executive Leadership Team.

Jim is a global growth strategist, transformational change catalyst, and next-generation life sciences technology executive with over 20 years’ experience driving breakthrough strategies, products, and services for top pharmaceutical companies, CROs, biotech innovators, and healthcare organizations. 

Jim will lead Envision’s global technology-enabled commercialization strategy and vision and be responsible for delivering upon its technology and innovation goals. He will oversee the overall efficiency and effectiveness of technology operations/systems and accelerate the delivery of innovative solutions and platforms for enhancements and synergies across Envision to support clients across the globe.

Prior to joining Envision, Jim served as Global Vice President at Oracle Health Sciences where he was responsible for driving development of the eClinical platform, launching new functionalities, expanding APAC market adoption, and leading key aspects of M&A product due diligence. Before Oracle, Jim served in multiple executive director roles at Pharmaceutical Product Development (PPD), assuming full leadership over electronic data capture, IT systems development, IT business engagement and delivery, eClinical strategy, and innovation. 

Jim shares, “I am excited to be joining Envision at such an important time for the company and the life sciences industry. There is a clear opportunity for Envision’s award-winning technology and people to increase its value to our customers and to life sciences. I am looking forward to accelerating Envision’s value through technology and innovation and engaging with its people, customers, and partners.” 

Meg Heim, Chief Executive Officer of Envision Pharma Group shares, “I am so excited to welcome Jim to the Envision team as our new President of Technology, CTO. Jim’s expertise will contribute directly to our foundational technology focus while accelerating our vision as a technology-enabled commercialization partner to the life sciences industry. This new and expanded role is instrumental to the fulfillment of our business expansion, mission, and commitment to our vision of leveraging innovative technology to support our clients.” 

Close

Envision Pharma Group is an exhibitor and Champion sponsor at the 19th Annual Meeting of ISMPP that is taking place from April 23–26 in Washington DC, USA.   

The meeting theme at this event is “Patients First” – so we are delighted to have great representation from our Envision the Patient team (Dawn Lobban, Catherine Elliott, Jacqui Oliver, and Amanda Boughey) who will be participating in plenary sessions, roundtables, and a workshop. Come and meet the team at booth #15 to discover how we connect our world-leading technology solutions with powerful scientific communications, driven by improving patient outcomes everywhere.

For a demonstration of how our technology solutions simplify collaborative reviews for research through services such as iEnvision® and doDOC®, or to find out more about what we can do, send a message to MeetMe@envisionpharma.com. 

We will be providing updates before, during, and after the event and sharing these through our social media page and this event web page, so check back soon. To read our insights from the European Meeting of ISMPP 2023, please click the button below. 

ISMPP EU 2023 Roundup

Close

We are proud to be an exhibitor and sponsor at the MAPS 2023 Global Annual Meeting on March 26–29 in Nashville. 

Meet the Envision team (Kim Cline, Christy Iannelli, Leif Masvaer, Jejett Miller, Brendan Fitzgerald, Francine Carrick, Synnove Smeets, Susanne Clark, Howard Miller, Morag Chambers, Emily Howman, and Kimberly Cash) at booth #14. 

Learn more about our services or request a meeting with the team at MeetMe@envisionpharma.com. 

We will be providing updates before, during, and after the event and will be sharing these through our social media page and this event web page, so check back soon. For the MAPS meeting schedule, click the button below. 

MAPS 2023 Global Meeting Schedule

 

Close

Envision Pharma Group (Envision) has appointed Pauline Bernard to the position of Regional Head, Commercial Strategy, Japan Asia-Pacific (JAPAC).

Pauline will help drive Envision’s global leadership as a technology-enabled commercialization, data analytics, and integrated medical capabilities and solutions partner to the life sciences industry. In her new position, she will be responsible for leading the development of Envision’s growth path throughout the JAPAC region.

With over 30 years of experience working in healthcare in JAPAC, Pauline brings a wealth of knowledge to the organization in this new role. Prior to joining Envision she has worked across several commercial and leadership functions within the top multinational pharmaceutical companies, and most recently in a management consulting practice with a focus on digital technology.

At Envision Pauline will lead its Tokyo and Sydney offices that have supported the JAPAC region and the organization’s global customers for many years. Pauline shares, “I am excited to join Envision at this moment in time and take part in the journey to integrate and seize the full potential of our products and services, while delivering positive outcomes for our clients and patients like we have never done before.”

Meg Heim, Chief Executive Officer of Envision Pharma Group, adds, “Pauline joining the Envision team is another layer in our strategic business expansion. With our legacy of tech-enabled commercialization, value and access and data analytics, and our medical capabilities and solutions for the life sciences industry, this new role is critical to the fulfillment of our business strategy and client success model supporting our clients in the JAPAC region, as well as across the globe to deliver 24-hour support to meet client needs.

“With our recent acquisition of OKRA.ai, now an Envision Pharma Company, we continue to enhance our innovative technology footprint while acquiring leading industry talent that supports our culture and people strategy for our internal and external customers.” 

 

Close

Envision Pharma Group is attending the MAPS webinar "Medical Affairs Contribution to an Integrated Omnichannel Strategy: Let's Get Started" on February 24. 

Kathryn Coles, Global Director Experimental Innovation at Envision Pharma Group, is moderating this discussion where panelists will share their insights on omnichannel considerations in medical affairs, including:

• A brief overview of omnichannel in medical affairs
• The critical components to achieving excellence in an omnichannel approach

We will be sharing a recording of the event once it’s available, so do check back soon.

Close

Envision Pharma Group (Envision), a leading global technology-enabled commercialization, integrated medical capabilities and solutions, and data analytics partner to the life sciences industry, announced today it has acquired OKRA.ai, an award-winning technology company active in the provision of artificial intelligence (AI) solutions with services across commercialization, real-world evidence and data analytics, medical, and pricing for the pharmaceutical and life sciences industry.

OKRA.ai’s AI products and solutions translate large clinical, scientific, and commercial data sets into actionable insights to empower decision-making and positive outcomes to clients in the life sciences industry.

“We are delighted to welcome OKRA.ai into the Envision family,” shares Meg Heim, CEO, Envision Pharma Group. “The acquisition of OKRA.ai marks an exciting milestone in Envision’s evolution as we continue to accelerate and deliver a compelling combination of technology-enabled capabilities and solutions to clients. The combination of Envision’s leading technology, capabilities, and solutions with OKRA.ai’s artificial intelligence expertise enables us to strengthen our offerings to clients across the product life cycle, but more importantly support patients in their journey to health and wellness.” 

Dr. Loubna Bouarfa, founder of OKRA.ai, will be joining Envision as a member of its Executive Leadership Team. Recently, Loubna won the prestigious Deloitte Fast 50 Women in Leadership Award and Forbes 50 Top Women in Tech. Loubna shares, “Today is a redefining moment for OKRA.ai. I am honored to be joining forces with Envision and to see the enormous opportunities for the growth of our combined expertise and solutions for clients in the life sciences industry. As part of Envision Pharma Group, we can accelerate our work to bring AI to the heart of decision-making across the life sciences industry. Our success will not only bring commercial benefit to clients, but lead to improved patient outcomes across the globe.” 

Based in the UK and Netherlands, OKRA.ai employs around 30 members of staff. The acquisition of OKRA.ai will bring the total number of Envision Pharma Group to 1400+ employees across four continents. 

Close

Envision Pharma Group (Envision) today announced the appointment of two senior executives while further expanding its global focus on M&A, technology-enabled solutions, and strategic consulting for the life sciences industry.

Dominic “Nick” Marasco has joined as Chief Commercial Officer of Envision Pharma Group, and member of the Executive Leadership Team. Nick is an experienced global commercial leader with nearly 30 years of pharmaceutical, biotech, and medical device industry experience. Having held several C-suite positions he has a proven track record of successfully launching and growing products and solutions with a focus on driving profitable revenue growth, building, and leading high-performing commercial organizations.

Nick will lead the development of Envision’s commercial-to-customer strategy while identifying new pathways to progression, with a focus on continuing its revenue growth and expanding its customer reach and solutions. He will help develop, lead, and reinforce Envision’s position as a technology-enabled commercialization, data analytics, and integrated medical capabilities and solutions company. Another key part of his role is to implement a coordinated and integrated sales structure across Envision to reinforce its technology-enabled positioning. 

Before joining Envision, Nick served as Chief Commercial Officer of BioAgilytix, supporting three buyer-side acquisitions and integrations, as well as one sell-side sale of BioAgilytix to new private equity owners. Prior to BioAgilytix, he served as Executive Vice President, Global Business Development, Commercial at Syneos Health, where he led the overall strategic direction of the global business development team for the commercial division, both in the US and internationally. 

Nick was also previously Head of US Sales for the Neuroscience Business Unit at Amgen, and prior to that Global Commercial Head, Amgen Biosimilars. He has also held executive-level commercial and business development positions at Sandoz Biopharmaceuticals (a Novartis company) and IQVIA (formerly Quintiles).

Nick shares, “It is a distinct pleasure to join both Meg Heim and the entire team at Envision Pharma Group. Envision is a company that is experiencing phenomenal growth and high customer engagement and loyalty across each of the pillars of the organization and has continued to realize the growing demand of customer needs and advisory services. Even better, Envision has excelled at progressive innovation via services and technology to achieve a comprehensive solutions-oriented service platform. I am excited to join this dynamic team.”

Gregory “Greg” Carpenter joins Envision Pharma Group as Chief of Staff, CEO, and member of the Executive Leadership Team and brings with him a wealth of global experience and expertise. 

Greg has held several leadership roles in the pharmaceutical industry and positions spanning sales, marketing, medical, and transformation. His expertise covers areas of communications, strategic planning and implementation, coalition and consensus-building leadership development, omnichannel marketing, and change management.

Before joining Envision, Greg’s most recent role was leading a go-to-market transformation for the Sanofi US General Medicines team that included building an enterprise artificial intelligence (AI) solution, and helping the organization understand and embrace omnichannel marketing. 

Greg says, “I am delighted to join Envision Pharma Group and help carry out our mission of improving lives through a compelling combination of technology and services to enable clients to better serve patients. Through our expertise in scientific and commercialization strategy and solutions, medical affairs, and AI-driven technology solutions, Envision is helping our customers to excel in a rapidly changing healthcare environment.”

Meg Heim, Chief Executive Officer of Envision Pharma Group, adds, “I am so excited to welcome Nick and Greg to the Envision team. These new positions are critical to the fulfilment of our business expansion, mission, as well as being a commitment to our vision that enables us to execute upon our strategic plans.” 

Close

Envision Pharma Group is an exhibitor and elite sponsor at the 2023 European Meeting of ISMPP that is taking place from January 24–25 in London, UK.   

Meet the Envision team (Dawn Lobban, Catherine Elliot, Lizzie Perdeaux, Hiroko Ebina, Andy Shepherd, Lauren Manning, Stephen Craig, and Leif Måsvær) at booth #9 to discover how we connect our world-leading technology solutions with powerful scientific communications, driven by improving patient outcomes everywhere. At our booth, you can contribute your own scribe illustration in support of the ISMPP meeting theme “fueling creativity”! 

For a demonstration of how our technology solutions simplify collaborative reviews for research through services such as iEnvision® and doDOC®, or to find out more about our services – request a meeting with the on-site team at MeetMe@envisionpharma.com.  

We will be providing updates before, during, and after the event and will be sharing these through our social media page and this event web page, so check back soon. For the “What's on at ISMPP EU 2023” information, click the button below. 

Close

The Envision Value & Access team shares key takeaways from the ISPOR EU meeting in Vienna earlier this month. You can access the report below.

For more information on how we can support your value and access strategy and communications in an evolving world, contact the team at: value@envisionpharma.com

Access the report

Envision Value & Access unites market access strategy and scientific communications expertise. Collaboration and partnership are at the core of our philosophy, bringing together experts from across Envision Pharma Group, patient collaborators, and client partners to support access to innovative health technologies.

Close

Any new drug launch must overcome numerous obstacles in the pursuit of success

“Any new drug launch must overcome numerous obstacles in the pursuit of success. Many of these challenges are exacerbated in oncology, where the treatment landscape rapidly evolves with novel mechanisms of actions (e.g., cell therapy, bi/tri-specific antibodies), where there are ever-changing regulatory requirements, the use of biomarkers, etc.” So how does this differ for a small and emerging biotech firm?”

In an article published earlier this year, Envision Pharma Group’s Rachel Shemer, along with Two Labs Angus Bromley and Kimberly Cash, discuss the advantages and challenges smaller companies face.

Close

Whitepaper

“To improve outcomes for cancer patients and take advantage of the groundbreaking scientific and technological progress made in oncology prevention, diagnosis, therapy, and care over recent years, it is of crucial importance to ensure all patients with cancer have a role and an ongoing dialogue with the healthcare team.”

Ensuring all patients with cancer have a role and an ongoing dialogue with their healthcare team is crucial.

In a whitepaper published earlier this year Envision Pharma Group’s Rebecca Goldstein, PhD, CMPP, and 90TEN’s Mark Lakeram discuss the value of diverse patient representation and engagement in cancer treatment.

Close

Envision Value & Access is an exhibitor and platinum sponsor at ISPOR EU 2022. As an insight-driven strategic consulting partner for clients and with a full array of HEOR and access services, from the development of your HEOR strategy and RWE roadmap through to evidence generation and communication, we work across functions to develop, communicate, and capture the value of products through a coherent and integrated payer strategy to improve patient access and outcomes globally.

Come meet Suki Kandola, Joe Merkert, and other Envision Value & Access team members at ISPOR Europe 2022, Booth X2-210!
November 6-9; Vienna, Austria

Want to meet at a specific day and time at the event? Then send a message to: Value@envisionpharma.com

Envision Value & Access has the following posters presented at ISPOR Europe 2022:

• “Deprivation and Access to Care Among Patients with Melanoma in the UK” 
  Vitaccess Ltd: Casey Quinn and Mark Larkin, Pfizer: Ira Jacobs, Envision Pharma Group: Suki Kandola and Karen E. Smoyer
   
• “A Comparison of the Evolution of Payer Management Practices in Oncology in the United States, Germany, France, and the United Kingdom, Over the Past Five Years”
  Envision Pharma Group: Anne Runyan, Janice Yi, Mounika Bodagala, Milos Pavic, and Thomas Schoenwaelder
   
• “Investigating How Orphan Drug Manufacturers Can Optimize Clinical Trial Design so Patients across Geographies Can Access Life-Saving Innovations​”
  Envision Pharma Group: Sheli Goldstein, Anne Runyan, Joe Merkert, Thomas Schoenwaelder, and Milos Pavic

Close